Advanced

Behandlingsprogram vid ascites. Rekommendationer fran Svensk forening for gastroenterologi och gastrointestinal endoskopi

Lööf, Lars; Prytz, Hanne LU ; Söderlund, Claes and Wallerstedt, Sven (2001) In Läkartidningen 98(49). p.5649-5655
Abstract
As ascites is related to liver cirrhosis in 80% of the patients, the present therapeutic guidelines are focused on ascites in liver cirrhosis. A combination of spironolactone and furosemide is recommended as first line therapy in patients with mild to moderate ascites and is effective in 90% of patients. In patients with pronounced or tense ascites, first line treatment is total paracentesis with intravenous infusion of human albumin as colloid replacement. Maintenance therapy for the prevention of recurrent ascites is based on spironolactone with or without furosemide. The indications for peritoneovenous shunt, or transjugular intrahepatic stent-shunt (TIPSS), are limited and only recommended in strictly selected patients with refractory... (More)
As ascites is related to liver cirrhosis in 80% of the patients, the present therapeutic guidelines are focused on ascites in liver cirrhosis. A combination of spironolactone and furosemide is recommended as first line therapy in patients with mild to moderate ascites and is effective in 90% of patients. In patients with pronounced or tense ascites, first line treatment is total paracentesis with intravenous infusion of human albumin as colloid replacement. Maintenance therapy for the prevention of recurrent ascites is based on spironolactone with or without furosemide. The indications for peritoneovenous shunt, or transjugular intrahepatic stent-shunt (TIPSS), are limited and only recommended in strictly selected patients with refractory ascites. Ascites in liver cirrhosis is a symptom of advanced liver disease, and liver transplantation should always be considered in eligible patients. (Less)
Please use this url to cite or link to this publication:
author
organization
alternative title
[Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy]
publishing date
type
Contribution to journal
publication status
published
subject
in
Läkartidningen
volume
98
issue
49
pages
5649 - 5655
publisher
Swedish Medical Association
external identifiers
  • pmid:11783052
  • scopus:0035814566
ISSN
0023-7205
language
Swedish
LU publication?
yes
id
2117ee8b-ab64-4520-82a7-62c6aaf2b059 (old id 1121512)
alternative location
http://ltarkiv.lakartidningen.se/artNo23883
date added to LUP
2008-07-04 11:41:57
date last changed
2018-01-07 09:10:36
@article{2117ee8b-ab64-4520-82a7-62c6aaf2b059,
  abstract     = {As ascites is related to liver cirrhosis in 80% of the patients, the present therapeutic guidelines are focused on ascites in liver cirrhosis. A combination of spironolactone and furosemide is recommended as first line therapy in patients with mild to moderate ascites and is effective in 90% of patients. In patients with pronounced or tense ascites, first line treatment is total paracentesis with intravenous infusion of human albumin as colloid replacement. Maintenance therapy for the prevention of recurrent ascites is based on spironolactone with or without furosemide. The indications for peritoneovenous shunt, or transjugular intrahepatic stent-shunt (TIPSS), are limited and only recommended in strictly selected patients with refractory ascites. Ascites in liver cirrhosis is a symptom of advanced liver disease, and liver transplantation should always be considered in eligible patients.},
  author       = {Lööf, Lars and Prytz, Hanne and Söderlund, Claes and Wallerstedt, Sven},
  issn         = {0023-7205},
  language     = {swe},
  number       = {49},
  pages        = {5649--5655},
  publisher    = {Swedish Medical Association},
  series       = {Läkartidningen},
  title        = {Behandlingsprogram vid ascites. Rekommendationer fran Svensk forening for gastroenterologi och gastrointestinal endoskopi},
  volume       = {98},
  year         = {2001},
}